Search results for "erythema"

showing 10 items of 243 documents

Interferon-α Abrogates the Suppressive Effect of Apoptotic Cells on Dendritic Cells in anIn VitroModel of Systemic Lupus Erythematosus Pathogenesis

2013

Objective.An increased incidence of apoptotic cells and an increased activation of dendritic cells (DC) may be involved in the pathogenesis of systemic lupus erythematosus (SLE). We investigated the characteristics of apoptotic neutrophils and monocyte-derived DC of patients with SLE, their interaction, and the influence of autoantibodies and inflammatory cytokines on this interaction.Methods.Kinetics of neutrophil apoptosis and DC activation were studied by flow cytometry. To analyze the interaction of apoptotic cells with phagocytes, crossover coculture experiments were performed with DC from patients with SLE and apoptotic Jurkat T cells as well as with apoptotic neutrophils from patient…

AdultMaleAdolescentInterleukin-1betaImmunologyAlpha interferonApoptosisJurkat cellsProinflammatory cytokineJurkat CellsRheumatologyInterferonHumansLupus Erythematosus SystemicImmunology and AllergyMedicineAgedAutoantibodiesU937 cellbusiness.industryInterleukin-17Interferon-alphaDendritic CellsU937 CellsMiddle AgedApoptosisImmunologyFemaleCytokine secretionInterleukin 17businessmedicine.drugThe Journal of Rheumatology
researchProduct

A Highly Decreased Binding of Cyclic Adenosine Monophosphate to Protein Kinase A in Erythrocyte Membranes is Specific for Active Psoriasis

2002

A cyclic adenosine monophosphate binding abnormality in psoriatic erythrocytes that could be corrected by retinoid treatment has been reported. It was tested whether this binding abnormality is specific for psoriasis and the effects of treatment were compared with etretinate, cyclosporine A, or anthralin on 2-(3)H-8-N(3)-cyclic adenosine monophosphate binding to the regulatory subunit of protein kinase A in erythrocyte membranes. One hundred and fifteen individuals were evaluated, including: (i) 34 healthy persons; (ii) 15 patients with nonatopic inflammatory skin diseases (eczema, erythroderma, tinea, Grover's disease, erysipelas, urticaria); (iii) eight with other dermatoses mediated by i…

AdultMaleAzidesmedicine.medical_specialtyAdolescentmedicine.drug_classAdministration TopicalAnti-Inflammatory AgentsErythrodermaEtretinateDermatologySeverity of Illness IndexBiochemistryRetinoidschemistry.chemical_compoundPsoriasis Area and Severity IndexKeratolytic AgentsPsoriasis Area and Severity IndexPsoriasisInternal medicineCyclic AMPmedicineHumansPsoriasisCyclic adenosine monophosphateRetinoidMolecular BiologydermatitisAgedErythema nodosumbusiness.industryErythrocyte MembraneAffinity LabelsCell BiologyAtopic dermatitisAnthralinMiddle Agedmedicine.diseaseCyclic AMP-Dependent Protein KinasesEndocrinologychemistryEtretinateCyclosporineFemaleDermatologic Agentsbusinesscyclosporine AProtein Bindingmedicine.drugJournal of Investigative Dermatology
researchProduct

Efficacy of mometasone furoate microemulsion in the treatment of erosive-ulcerative oral lichen planus: pilot study

2004

Background:  Oral lichen planus (OLP) is a frequent immunological chronic disease, having different clinical forms: asymptomatic and symptomatic. Symptomatic OLP has been palliated with topical corticosteroids with different levels of efficacy and safety. The purpose of this pilot phase II clinical trial was to determine the efficacy of mometasone furoate microemulsion upon the symptoms and signs of erosive-ulcerative OLP. Methods:  Forty-nine patients with clinical and histologically confirmed erosive-ulcerative OLP were enrolled in this study (36 women and 13 men). Their average age was 56.4 years (from 28 to 78). The treatment consisted of 0.1% mometasone furoate microemulsion mouthwash …

AdultMaleCancer Researchmedicine.medical_specialtyErythemamedicine.drug_classAdministration TopicalAnti-Inflammatory AgentsMouthwashesMometasone furoatePilot ProjectsAsymptomaticPathology and Forensic Medicinestomatognathic systemHumansMedicineAdverse effectGlucocorticoidsPregnadienediolsAgedbusiness.industryMometasoneMiddle Agedmedicine.diseaseDermatologyClinical trialstomatognathic diseasesOtorhinolaryngologyPeriodonticsCorticosteroidEmulsionsFemaleOral lichen planusOral Surgerymedicine.symptombusinessMometasone FuroateLichen Planus Oralmedicine.drugJournal of Oral Pathology and Medicine
researchProduct

Stereotactic fractionated radiotherapy in patients with optic nerve sheath meningioma.

2002

Abstract Purpose: To evaluate the effectiveness of stereotactic fractionated radiotherapy (SFRT) in the treatment of optic nerve sheath meningioma (ONSM). Methods and Materials: Between 1994 and 2000, a total of 39 patients with either primary ( n = 15) or secondary ( n = 24) ONSM were treated with SFRT and received a median total tumor dose of 54 Gy using 1.8 Gy/fraction. Results: The radiographic response to SFRT was documented in all patients as stable disease (no change) except for 1 patient with a partial response. After a median follow-up of 35.5 months, all patients with ONSM were alive without recurrence. The visual fields and visual acuity were improved in 6 of 15 and 1 of 16 exami…

AdultMaleCancer Researchmedicine.medical_specialtyVisual acuityTime FactorsFractionated radiotherapyErythemaAdolescentRadiographyRadiosurgerymedicineHumansRadiology Nuclear Medicine and imagingIn patientAge of OnsetAgedAged 80 and overRadiationbusiness.industryStandard treatmentOptic Nerve NeoplasmsDose fractionationMiddle Agedmedicine.diseaseSurgeryOptic nerve sheath meningiomaTreatment OutcomeOncologyDisease ProgressionFemaleRadiologyDose Fractionation Radiationmedicine.symptombusinessMeningiomaFollow-Up StudiesInternational journal of radiation oncology, biology, physics
researchProduct

Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study.

2016

Objective The aim of the study was to assess the efficacy and safety of fumaric acid esters (FAEs) in patients with cutaneous lupus erythematosus (CLE). Methods In this 24-week, prospective, open-label, phase II pilot study, 11 patients with CLE, refractory to topical corticosteroids, were included. The primary endpoint of the study was the evaluation of the efficacy of FAEs after 24 weeks of treatment as assessed by the Revised Cutaneous Lupus Disease Area and Severity Index (RCLASI). Results Compared to baseline, significant improvement in the mean total RCLASI activity score and the mean RCLASI activity score for skin lesions was observed in week 12 ( p = 0.002, p = 0.002, respectively) …

AdultMaleFumaric acidmedicine.medical_specialtyColicPilot ProjectsSeverity of Illness IndexDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRheumatologyFumaratesLupus Erythematosus CutaneousMedicineHumansIn patientProspective Studies030203 arthritis & rheumatologybusiness.industryHeadacheMiddle AgedDermatologyAlternative treatmentClinical trialTreatment OutcomeFumaric Acid EsterschemistryCutaneous Lupus ErythematosusFemaleOpen labelbusinessLupus
researchProduct

Characterization of non-expressed C4 genes in a case of complete C4 deficiency: identification of a novel point mutation leading to a premature stop …

1998

The genetic basis of complete C4 deficiency in a patient with SLE was investigated. Previous studies have demonstrated that this patient has two different major histocompatibility complex (MHC) haplotypes that each contain a major deletion and a non-expressed C4 gene. In the present study, non-expression of the C4 genes was explained by the finding of two distinct C4 gene mutations. A previously described two base pair insertion in exon 29 of the C4 gene was detected in the paternal MHC haplotype [HLA-A2, B40, SC00, DR6]. The maternal haplotype [HLA-A30, B18, F1C00, DR3] carried a C4 gene with a one base pair deletion in exon 20 generating a premature stop codon. This mutation was neither f…

AdultMaleHeterozygoteImmunologyGene mutationBiologymedicine.disease_causePolymerase Chain ReactionCell LineMajor Histocompatibility ComplexExonmedicineImmunology and AllergyHumansLupus Erythematosus SystemicPoint MutationGenePolymorphism Single-Stranded ConformationalGeneticsMutationPoint mutationHaplotypeC4AComplement C4General MedicineExonsSequence Analysis DNAMolecular biologyIsotypePedigreeHaplotypesCodon TerminatorFemalePolymorphism Restriction Fragment LengthHuman immunology
researchProduct

Molecular basis of a new type of C1q-deficiency associated with a non-functional low molecular weight (LMW) C1q: parallels and differences to other k…

1998

Analysis of an abnormal C1q molecule of individuals of a Moroccan family by ultracentrifugation in sucrose gradients revealed a low molecular weight C1q (LMW-C1q). We investigated the molecular basis of this defect by sequencing all six exons of the three C1q genes. One point mutation in the codon for Gly at position 15 (GGT) of the B chain was found resulting in an amino acid substitution to Asp (GAT). The exchange not only leads to an interruption of the collagen-like motif Gly-X-Y, but also introduces one negatively charged residue per B chain which results in two additional charges per structural subunit (A-B, C-C, A-B). The mutation which has been identified by DNA-sequencing in the C1…

AdultMaleImmunodiffusionAdolescentSequence analysisProtein subunitchemical and pharmacologic phenomenaBiologyComplement Hemolytic Activity AssayPolymerase Chain Reactionlaw.inventionExonlawHumansLupus Erythematosus SystemicPoint MutationChildGenePolymerase chain reactionPharmacologychemistry.chemical_classificationPoint mutationComplement C1qDNAExonsMolecular biologyAmino acidMolecular WeightMoroccoBiochemistrychemistryFemaleUltracentrifugeCollagenSequence AnalysisImmunopharmacology
researchProduct

An exploratory, prospective, open-label trial of ingenol mebutate gel 0.05% for the treatment of external anogenital warts

2017

BACKGROUND Anogenital warts (AGW) can cause physical discomfort and decreased quality of life. Recent case reports suggest that ingenol mebutate gel might be an effective treatment of AGW. OBJECTIVE To explore primarily the safety, and secondarily the efficacy of ingenol mebutate gel 0.05% in patients with AGW. METHODS This was an exploratory, open-label, 1-arm trial of ingenol mebutate gel 0.05% administered up to three times to patients with AGW. Safety was assessed by occurrence and severity of local skin reactions (LSRs) and treatment-related adverse events (AEs). Efficacy was assessed by complete clearance and reduction in AGW count 14 days after last treatment, and recurrence 12 weeks…

AdultMaleIngenol Mebutate Gelmedicine.medical_specialtyPopulationPainAntineoplastic AgentsDermatologyYoung Adult030207 dermatology & venereal diseases03 medical and health sciencesBlister0302 clinical medicineQuality of lifeRecurrenceInternal medicineSkin UlcermedicineEdemaHumansEffective treatmentIn patientProspective Studies030212 general & internal medicineAdverse effecteducationAgedAnus Diseaseseducation.field_of_studybusiness.industryMiddle AgedSafety profileTreatment OutcomeInfectious DiseasesCondylomata AcuminataErythemaFemaleDiterpenesGenital Diseases MaleOpen labelbusinessGelsGenital Diseases FemaleJournal of the European Academy of Dermatology and Venereology
researchProduct

Value of videoroscopy in the detection of alterations of  Actinic Cheilitis and the selection of biopsy areas

2015

Background To demonstrate the value of videoroscopy in identifying lesions and alterations not seen by oroscopy and to select the area for biopsy. Material and Methods Eighty patients were subjected to anamnesis, physical exam, videoroscopy exam, toluidine blue test and biopsy. A diagram of the lips was created to record the exact location where the lesion was found. Results Physical exam identified 287 lesions, and videoroscopy identified 587 lesions; erythema and white lesions were the most common lesions associated with actinic cheilitis. Of the 59 performed biopsies, 32 (52.4%) cases were identified by videoroscopy that showed lesions that were not detected during physical examination. …

AdultMalePathologymedicine.medical_specialtyErythemaAdolescentBiopsyVideo RecordingOdontologíaPhysical examinationLesionYoung AdultBiopsyMedicineHumansExact locationOral DiagnosisChildGeneral DentistryAgedAged 80 and overOral Medicine and Pathologymedicine.diagnostic_testbusiness.industryActinic cheilitisResearchDiagnosis OralMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludDermatologyLipOtorhinolaryngologyCheilitisUNESCO::CIENCIAS MÉDICASSurgeryPhysical examFemalemedicine.symptombusinessMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Epidemiology of desquamative gingivitis: evaluation of 125 patients and review of the literature

2009

Background  Desquamative gingivitis (DG) is a descriptive term used to indicate epithelial desquamation, erythema, erosions, and/or vesiculobullous lesions of the gingiva. DG is commonly associated with several mucocutaneous disorders and systemic conditions that may carry a poor prognosis and high morbidity; however, there are no clear data concerning the frequency of these disease associations. Methods  We investigated the epidemiologic features of DG in 125 patients and compared our findings with information from a literature review. Results  In our series, 88% of patients with DG had one of the following three disorders: oral lichen planus (OLP), mucous membrane pemphigoid (MMP), or pem…

AdultMalePathologymedicine.medical_specialtyErythemaAdolescentMucocutaneous zoneDermatologyGingivitisYoung AdultSettore MED/28 - Malattie OdontostomatologicheEpidemiologymedicineHumansSex organepidemiology desquamative gingivitisAgedAged 80 and overbusiness.industryPemphigus vulgarisMiddle Agedmedicine.diseaseDermatologyGingivitisDesquamative gingivitisstomatognathic diseasesOral lichen planusFemalemedicine.symptombusiness
researchProduct